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The degree of airway inflammation is directly related to asthma severity and 
associated hyper-responsiveness. Airway inflammation is categorized into three 
types: (a) acute asthmatic inflammation featured by early recruitment of cells into 
the airways, (b) subacute asthmatic inflammation involving activation of recruited 
cells in continual inflammation, and (c) chronic inflammation characterized by cel-
lular damage. T-helper lymphocytes, the key factor in the pathogenesis of bronchial 
asthma, induce B cells to synthesize and secrete IgE through production of IL-4 
and induce eosinophil-mediated inflammation. Mediators such as histamine, PG, 
leukotrienes, and kinins contract airway smooth muscle, increase microvascular 
leakage, increase airway mucus secretion, and attract other inflammatory cells into 
airway epithelia that initiate mucociliary clearance signaling pathways through 
special Toll-like receptor 4 expressed on epithelial cells activated by allergic and 
infectious triggers. These cells form barrier against mechanical stress, oxidant 
stress, allergens, pollutants, infectious agents, and leakage of endogenous solutes. 
Various adhesion molecules and costimulatory factors also promote infiltration of 
inflammatory cells at the site of inflammation.
Keywords: airway inflammation, hyper-responsiveness, bronchial asthma,  
T-helper lymphocytes, mediators
1. Introduction
The inflammatory response in asthmatic airways is a complex interplay between 
respiratory epithelium and immune system. The drive for a chronic inflammatory 
response initiates with production of bioactive mediators from airway epithelium, 
which attracts, activates, and recruits the inflammatory cells into lung airways. 
Infiltrated cells augment inflammatory response through the release of other 
biochemical mediators. The inflammatory mediators released by these cells are the 
effectors of chronic inflammation including cytokines classified into lymphokines 
or immunomodulatory cytokines released by T-helper cells, proinflammatory 
cytokines that promote and amplify the inflammatory response, chemokines that 
are chemoattractants for leukocytes, growth factors that promote cell survival, and 
eicosanoid lipid mediators that have multiple effects in the airway. The products 
released from leukocytes and epithelial cells induce bronchospasm, damage the epi-
thelium, stimulate airway cells, and recruit additional leukocytes creating a cycle of 
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inflammation that becomes chronic. In acute cases of allergen exposure, mast cells 
can provide an early source of proinflammatory mediators such as IL-4 and IL-5. 
Episodes of acute inflammatory reactions are often accompanied by an underlying 
chronic inflammation even in the absence of continuous allergen exposure.
2. Airway inflammation in asthma
The degree of airway inflammation and corresponding airway hyper-respon-
siveness (AHR) is related to clinical symptoms in asthma. Asthmatic inflammation 
is categorized into three types: (a) acute asthmatic inflammation featured by early 
recruitment of cells into the airways, (b) subacute asthmatic inflammation involving 
activation of recruited cells in continual inflammation, and (c) chronic inflammation 
characterized by cellular damage. Various types of biogenic mediators that play an 
important part in inflammatory process in asthmatic airways are given in Figure 1.
2.1 Cells
2.1.1 Eosinophils
Eosinophil infiltration is a characteristic feature of asthmatic airway inflam-
mation that plays a central role in asthma. Allergen inhalation results in a marked 
increase in eosinophil count in bronchoalveolar (BAL) fluid at the time of the late 
asthma response with a decrease in peripheral eosinophil counts with the appearance 
of eosinophil precursors in the circulation. Recruitment of eosinophils to airways is 
mediated by interleukin (IL)-13, histamine, prostaglandin type 2, and chemokines, 
such as RANTES (regulated on activation T-cell expressed and secreted), eotaxins, 
and macrophage chemotactic protein (MCP)-4, expressed in epithelial cells [1, 2].
2.1.2 Neutrophils
Neutrophils are predominantly observed in the airways and sputum of patients 
with severe asthma [3], especially during acute exacerbations of asthma and in 
some patients with long-lasting or corticosteroids dependent or unresponsive to 
inhaled steroids. They are recruited through Th17 pathways and lead to increased 
concentrations of IL-8 in sputum, which in turn may be due to the increased levels 
Figure 1. 
Inflammatory mediators in asthma.
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of oxidative stress in severe asthma [4]. Neutrophils contribute to BHR and airway 
inflammation through the release of mediators like PAF, thromboxanes, and leukot-
rienes and tissue damage through secretion of proteases and oxygen radicals [5].
2.1.3 Macrophages
Macrophages, derived from blood monocytes, extend inflammatory process 
in asthma through production of a variety of cytokines, after being activated by 
allergen via low-affinity IgE receptors (FceRII) [6]. Macrophages may both increase 
and decrease inflammation, depending on the stimulus. Alveolar macrophages nor-
mally have a suppressive effect on lymphocyte function, but this may get impaired 
in asthma after allergen exposure [7]. Macrophages secrete an anti-inflammatory 
protein IL-10 which is reduced in alveolar macrophages from patients with asthma 
[8]. Macrophages may, therefore, play an important anti-inflammatory role, by 
preventing the development of allergic inflammation [9].
2.1.4 Mast cells
Mast cells are central to the development of type I hypersensitivity reaction. 
Mast cells are bone marrow-derived cells widely distributed in the body predomi-
nantly near blood vessels, subepithelial cells and nerves, mucosal lining of the gut, 
and upper and lower respiratory tract. Increased numbers of degranulated mast 
cells have been found in asthma exacerbation [10]. Mast cells contain membrane-
bound granules filled with biologically active mediators.
After re-exposure, mast cells get activated by cross-linking of high-affinity 
IgE Fc receptors present on mast cell surface or by stimuli such as C5a and C3a 
(anaphylatoxins) and release a wide variety of mediators that result in acute 
bronchospasm or perpetuate underlying inflammation through cytokines [11]. Mast 
cells are an important source of histamine, cysteinyl leukotrienes, prostaglandins, 
cytokines, and platelet-activating factor, after getting activated by binding of stem 
cell factor to the surface receptor c-kit, IgE cross-linking, or binding of tyrosine 
kinase [12], and the process is called degranulation of mast cells (Figure 2).
2.1.5 T-lymphocytes
Several types of T-lymphocytes (especially, Th1, Th2, Th9, and Th17) play an 
important role in coordinating the inflammatory response in asthma through 
release of a number of cytokines. Traditionally, Th2 cells have been thought to pre-
dominate, with characteristic raised levels of IL-4, IL-5, and IL-13. High proportion 
of TH1 cells that can develop under the influence of IL-18 and interferon γ (IFN-γ) 
associated with further production of IFN-γ is found in some asthmatics. Th17 
cells, expressing IL-17, also play an unusual role in asthmatic patients [13]. Th17 are 
CD4-positive T cells and result in neutrophils influx. Th9 levels are raised in people 
with atopy cells, secrete IL-9, and promote allergic responses, probably through 
activation of mast cells. T-regulatory cells, characterized by secretion of transform-
ing growth factor β (TGF-β) and IL-10, are thought to be important because of their 
role in blunting atopic responses [14].
2.1.6 B-lymphocytes
B cells are important in asthma associated with atopy because they produce IgE. Their 
survival is supported by IL-5 and a B-cell-activating factor. B cells need to bind to T 
cells under the influence of IL-4 or IL-13. Secreted IgE are primarily bound through the 
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high-affinity Fc receptors on mast cells and basophils, and when cross-linked by aeroal-
lergen, it causes these cells to degranulate and release their mediators [15].
2.1.7 Innate lymphoid cells
ILCs are a family of immune cells that are defined by several features including 
the absence of recombination-activating gene (RAG)-dependent rearranged antigen 
receptors, their lymphoid morphology, as well as lack of myeloid phenotypic mark-
ers and are therefore called cell lineage marker-negative (Lin−) cells. These ILCs are 
present in the skin, adipose tissues, mesenteric lymph nodes, tonsils, and spleen and 
mediate inflammatory pathways in various diseases of the lungs and skin. ILCs are clas-
sified into three groups according to their transcription factors and cytokine produc-
tion profile that resembles T-helper (TH) cell subsets [16]. Among these cells, group 2 
innate lymphoid cells (ILC2s) are known to play a role in pathogenesis of type 2 inflam-
matory diseases of the lungs and skin such as asthma and atopic dermatitis [17]. They 
have the capacity to produce type 2 (TH2) cytokines and interact with both immune 
and nonimmune cell populations in the local tissue environment. ILC1s produce TH1 
inflammatory cytokines, particularly IFN-γ and tumor necrosis factor (TNF-α). They 
play their role in the pathogenesis of chronic obstructive pulmonary disease (COPD) 
and human inflammatory bowel (IBD). ILCs generally differentiate into macrophages 
and granulocytes while stimulating eosinophils and producing Th2 cytokines [18].
Figure 2. 
Activation of mast cells and release of mediators in allergic asthma.
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2.1.8 Airway epithelial cells
Airway epithelial cells play an important role in mucociliary clearance signaling 
through special receptors Toll-like receptor 4 expressed on epithelial cells activated by 
allergic and infectious triggers. These cells form barrier against mechanical stress, oxi-
dant stress, allergens, pollutants, infectious agents, and leakage of endogenous solutes. 
In asthma, epithelial cell-derived cytokines and chemokines (including IL-25, IL-33, 
thymic stromal lymphopoietin [TSLP], and granulocyte-macrophage colony-stimulat-
ing factor [GM-CSF]) signal effector cells (including basophils, eosinophils, mast cells, 
and lymphocytes) and dendritic cells are of importance in developing characteristic 
asthmatic immune response patterns to various types of allergic stimuli [19].
2.1.9 Dendritic cells
Like airway epithelial cells, pulmonary dendritic cells are also directly exposed 
to the external environment. These dendritic cells act as antigen-presenting cells 
and are directly stimulated by allergens or infectious agents directly after binding 
with recognition receptors or indirectly stimulated by airway epithelial cells (by 
mediators such as IL-25, IL-33, GM-CSF); dendritic cells can recruit eosinophils 
in allergen-presenting regions [20]. Dendritic cells are also found to effect T-cell 
differentiation and generate Th2 response commonly seen in atopic asthma [21].
2.2 Adhesion molecules
These molecules promote infiltration of inflammatory cells at the site of inflam-
mation, recruitment of leukocytes from vascular lumen to tissues, and cell activa-
tion [22]. Adhesion molecules are upregulated in allergic inflammation and play a 
critical role in pathogenesis inflammation. More than 35 adhesion molecules have 
been identified, for example, integrins, immunoglobulin supergene family, selec-
tins, and carbohydrate ligands including ICAM-1 and VCAM-1.
2.3 Costimulatory factors
A number of costimulatory factors are known to play an important role in the 
development of immunity such as inducible costimulator (ICOS) and ligand for 
ICOS. ICOS is known to regulate production of Th2 cytokines and to have a signifi-
cant role in lung mucosal inflammatory responses [23, 24].
2.4 Inflammatory mediators
A number of mediators that account for pathophysiological features of allergic 
diseases have been implicated in asthma. Mediators such as histamine, PG, leukot-
rienes, and kinins contract airway smooth muscle, increase microvascular leakage, 
increase airway mucus secretion, and attract other inflammatory cells.
2.4.1 Histamine
Histamine was the first mediator known to be implicated in pathophysiology of 
asthma. Histamine is synthesized and released by mast cells and basophils in the 
airways. Histamine causes mucus secretion and bronchoconstriction which is par-
tially mediated by vagal cholinergic reflex. Histamine also acts as a chemoattractant 
for eosinophils and activates eosinophils [25].
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2.4.2 Leukotrienes
The cysteinyl leukotrienes, LTC4, LTD4, and LTE4, are eicosanoids derived from 
arachidonic acid by 5-LOX (lipoxygenase) pathway. They are potent constrictors 
of human airway and have been reported to increase AHR and play an important 
role in asthma [3]. They constitute the slow-reacting substance of anaphylaxis. [26]. 
Potent LTD4 antagonists protect (by 50%) against exercise- and allergen-induced 
bronchoconstriction, suggesting that leukotrienes contribute to bronchoconstrictor 
responses.
2.4.3 Platelet-activating factor
Platelet-activating factor (PAF) is a potent inflammatory mediator that mimics 
many features of asthma, including eosinophil recruitment and activation and induc-
tion of AHR, plasma exudation, and mucus hypersecretion. The high level of lyso-
PAF (metabolite of PAF) is analyzed in BALF of patients with allergic asthma [27].
2.4.4 Prostaglandin
Prostaglandins are generated from arachidonic acid by cyclooxygenase (COX) 
pathway. Increased concentration of PGF2, PGD2, and thromboxane B2 in bron-
choalveolar (BAL) fluid of asthmatics is found. When inhaled, they cause broncho-
constriction [28] and increase airway responsiveness to spasmogen.
2.4.5 Proteases
Tryptase is a mast cell serine protease and plays a role in hemostasis, mucus secre-
tion, and vascular permeability. Elevated levels of tryptase have been found in BAL 
fluid and sputum of asthmatic patients after allergen challenge [29]. Elevated levels 
of MMP-9 (metalloproteinase-9), a protease released by eosinophils and alveolar 
macrophages, are found in bronchoalveolar fluid from asthmatic patients [30].
2.4.6 Kinins
Kinins are vasoactive peptides secreted from kininogens by the action of kinin-
ogenase during the inflammatory response. Bradykinin is an important kinin that 
has many effects on airway functions mediated by direct activation of B2 receptors 
of airway smooth muscles. Bradykinin activates alveolar macrophages to release 
LTB4 and PAF and activates nociceptive nerve fibers in the airways of asthmatic 
patients only which may mediate cough and chest tightness characteristic features 
of asthma [31] .
2.4.7 Cytokines
Cytokines are extracellular signaling proteins secreted by almost every cell 
under certain conditions and play a critical role in orchestrating all types of inflam-
matory response in asthma [32]. They act on target cells to cause a wide range of 
cellular functions like activation, proliferation, chemotaxis, immunomodulation, 
release of inflammatory mediators, growth and cell differentiation, and apoptosis. 
In contrast to acute and subacute inflammatory responses, cytokines play a domi-
nant role in maintaining chronic inflammation in allergic diseases. The important 
cytokines in asthma are lymphokines secreted by T-lymphocytes: IL-1β, IL-3, 
IL-4, IL-5, IL-6, IL-9, IL-13, TNF-α, etc. where IL-3 is reported to be crucial for 
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the survival of mast cells in tissues, but IL-4 plays an important role in switching 
B-lymphocytes to produce IgE and expression of VCAM-1 on endothelial cells. IL-5 
plays a critical role in differentiation, survival, and priming of eosinophils, thus 
promoting eosinophilic inflammation, and present in BAL fluid during allergen-
induced late-phase asthma [33]. Airway macrophages are important source of 
IL-1β, TNF- α, and IL-6 which act on epithelial cells to release GM-CSF, IL-8, and 
RANTES and amplify the inflammatory response leading to influx of secondary 
cells like eosinophils [34].
2.4.7.1 Proinflammatory cytokines
IL-9 and IL-13 are considered as proinflammatory cytokines. IL-9 is known 
to stimulate proliferation of activated T cells, enhancing IgE production from B 
cells, promoting proliferation and differentiation of mast cells, upregulating the 
α-chain of the FcεRI receptor, and inducing CC chemokine expression in lung 
epithelial cells contributing in allergen-induced airway changes. IL-13 is present 
in increased amounts in asthmatic airways and possesses biological activities 
similar to IL-4 [35]. Unlike IL-4 which is central to development of Th2 cells 
during primary sensitization, IL-13 release is more important during secondary 
antigen exposure [36].
Another group of proinflammatory cytokines are TNF-α that help in leukocyte 
recruitment through upregulation of adhesion molecules on vascular endothelial 
cells and induction of cytokine and chemokine synthesis airway hyper-responsive-
ness and pathogenesis of airway remodeling [37].
2.4.7.2 Immunomodulatory cytokines
IL-10, IL-12, IL-18, and interferon gamma (IFN-γ) are known as immuno-
modulatory cytokines. IL-10 is a pleiotropic cytokine that has the potential to 
downregulate both Th1- and Th2-driven inflammatory processes [38] and beneficial 
effect on airway remodeling [39]. IL-12 is released by antigen-presenting cells and is 
known to play an important role in Th1/Th2 differentiation during primary antigen 
presentation [40]. IL-18 is secreted by macrophages [41], and IFN-γ is reported to 
Figure 3. 
Cytokines involved in the pathogenesis of bronchial asthma.
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prevent the development of antigen-induced airway eosinophilia and hyper-respon-
siveness [42]. IL-12 and IL-18 act synergistically for inducing IFN-γ and inhibiting 
IL-4-dependent IgE synthesis as well as inhibiting allergen-induced airway hyper-
responsiveness [43]. Balance between Th1 and Th2 cells is thought to be determined 
by locally released cytokines, such as IL-12, which favor emergence of Th1 cells; 
contrary to this, IL-4 and IL-13 favor the growth of Th2 cells (Figures 3 and 4).
2.4.8 Chemokines
Chemokines are chemotactic cytokines responsible for recruitment of inflam-
matory cells in the airways. Chemokines have been categorized into two main 
groups, (a) CXC (α-type) and CC (β-type) chemokines, and exert their effects 
through G-protein-coupled chemokine receptors (CCR) [44]. Exacerbation of 
asthma leads to the synthesis and release of a number of chemokines. Increased 
expression of eotaxin, eotaxin-2, MCP-3, MCP-4, and CCR3 in the airways of 
asthmatic patients is found, and this can be correlated to increased AHR [45].
2.4.9 Tachykinins
Tachykinins are neuropeptides derived from preprotachykinins (PPTs). They 
are released by sensory nerves of airways and stimulate mucus secretion, plasma 
exudation, neural activation, bronchoconstriction, and structural changes. These 
peptides activate macrophages and monocytes to release inflammatory cytokines, 
IL-6 [46]. Higher concentration of a tachykinin, substance-P (SP), has been found 
in BALF of asthmatic lungs [47].
2.4.10 Endothelins
Endothelins are peptide mediators secreted via endothelin-converting 
enzyme (ECE) through mRNA present in airway epithelial cells and regulated 
by a number of proinflammatory cytokines in asthma. The biological effects of 
endothelins are mediated by two receptors: ETA and ETB. Endothelins are potent 
Figure 4. 
Release of mediators after allergen exposure to airway epithelia.
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bronchoconstrictors and induce airway smooth muscle cell proliferation and fibro-
sis and play an important role in chronic inflammation of asthmatic airways [48]. 
After the allergen challenge, endothelins (ETs) are secreted de novo. Higher levels 
of endothelin-1 are found in the sputum of asthmatic patients [49].
2.4.11 Neural mediators
Several nonadrenergic-noncholinergic (NANC) nerves and neuropeptides have 
been identified in the respiratory tract. Airway nerves may also release neurotrans-
mitters that have inflammatory effects such as substance P (SP), neurokinin A, 
and calcitonin gene-related peptide, may be released from sensitized inflammatory 
nerves in the airways, and perpetuate the ongoing inflammatory response. Thus, 
chronic asthma may be associated with increased neurogenic inflammation, which 
may provide a mechanism for prolonging the inflammatory response even in the 
absence of initiating inflammatory stimuli.
2.5 Antibodies
Antibodies are protein molecules released by immune system in response to 
foreign bodies, allergens. Five classes of antibodies, namely, IgM, IgG, IgA, IgD, 
and IgE [48], are known. Of these IgE is the predominant antibody in asthma 
in humans. IgE is the antibody responsible for all types of allergic reaction and 
pathogenesis of allergic asthma and development of inflammation in the human 
body. Elevated levels of IgE are found in bronchial asthma. Monoclonal antibodies 
against IgE have shown the reduction of IgE and associated asthma symptoms in 
asthmatics [50].
2.6 Oxidative stress
The increased level of oxidative stress found in airways of people with allergic 
asthma activates circulatory inflammatory cells, such as macrophages and eosino-
phils. Activated inflammatory cells produce more number of reactive oxygen 
species causing Increased concentrations of 8-isoprostane (a product of oxidized 
arachidonic acid) [51] and ethane (a product of oxidative lipid peroxidation) in 
exhaled breath of asthmatic patients [52]. Increased oxidative stress can be related 
to disease severity and may amplify the inflammatory response and reduce respon-
siveness to corticosteroids, particularly in severe disease and during exacerbations. 
Mechanism underlying the role of oxidative stress in asthma severity may be due 
to reaction of superoxide anions with nitric oxide (NO) forming reactive radical 
peroxynitrites that may modify several target proteins.
2.7 Nitric oxide (NO)
Measurement of the level of NO in exhaled air of asthmatic patients is increas-
ingly being used as a noninvasive way of monitoring the inflammatory process 
[53]. NO is produced by NO synthase, but in epithelial cells of asthmatic patients, 
the enzyme inducible of NO synthase (iNOS) is present. Recent studies report the 
higher level of NO in the exhaled air of patients with asthma than the level of NO 
in the exhaled air of normal subjects. The combination of increased oxidative stress 
and NO may lead to the formation of the potent radical peroxynitrite that may 
result in nitrosylation of proteins in the airways [54]. Since NO is a potent vasodila-
tor, this may increase plasma exudation in airways, and it may also amplify the 
Th2-mediated response.
Asthma - Biological Evidences
10
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Poonam Arora* and S.H. Ansari
Jamia Hamdard, New Delhi, India
*Address all correspondence to: poonamarora96@gmail.com
3. Airway remodeling
The acute and chronic allergic inflammatory responses in asthmatic lungs 
result in epithelial shedding, goblet cell hyperplasia, basal membrane thickening, 
subepithelial fibrosis in peribronchial interstitial tissue, hyperplasia of airway 
smooth muscle cells, angiogenesis, and dysfunctioning of bronchial blood vessels 
[55]. These changes contribute to alteration in lung anatomy termed as airway 
remodeling and are represented by increased thickness of the basement membrane 
and increased volume of airway smooth muscle associated with increases in growth 
factors, including TGF-β1 and platelet-derived growth factor, in Th2-driven models 
of asthma [56–58]. Overexpression of Th2 interleukins, especially IL-4, IL-5, and 
IL-13, is known to produce demonstrative changes in asthmatic airways. Increased 
expression of IL-13 causes subepithelial fibrosis, mucus metaplasia, and infiltration 
of eosinophils and macrophages, whereas increased expression of IL-4 and IL-5 
induced airway eosinophilia, mucus metaplasia, and subepithelial fibrosis.
4. Conclusion
Complex interactions among various bioactive mediators in asthmatic lungs 
make it a complex disease and therefore need a more detailed research studies to 
discern its complete physiology.
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